Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Ultragenyx Pharmaceu (RARE)

Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Dec 20, 3:30PM CST

RARE : 44.22 (+1.73%)
RARE Submits BLA to the FDA for Sanfilippo Syndrome Gene Therapy
RARE Submits BLA to the FDA for Sanfilippo Syndrome Gene Therapy Zacks Investment Research - Fri Dec 20, 11:38AM CST

Ultragenyx Pharmaceutical RARE announced that it has submitted a biologics license application (BLA) to the FDA for its UX111 (ABO-102) AAV gene therapy as a treatment for patients with Sanfilippo syndrome...

CTMX : 1.0900 (-0.91%)
RARE : 44.22 (+1.73%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)
Ultragenyx Pharmaceutical Inc. Doses First Patient in Pivotal Phase 3 Aspire Study for GTX-102 in Angelman Syndrome Quiver Quantitative, Inc. - Fri Dec 20, 1:24AM CST

Ultragenyx initiates Phase 3 study of GTX-102 for Angelman syndrome, assessing safety and efficacy in 120 children.Quiver AI SummaryUltragenyx Pharmaceutical Inc. announced the dosing of the first patient...

RARE : 44.22 (+1.73%)
Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome GlobeNewswire - Thu Dec 19, 3:05PM CST

RARE : 44.22 (+1.73%)
Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA) GlobeNewswire - Thu Dec 19, 7:00AM CST

RARE : 44.22 (+1.73%)
Insider Sale: President & CEO of $RARE (RARE) Sells 8,273 Shares Quiver Quantitative, Inc. - Thu Dec 12, 4:02AM CST

EMIL D KAKKIS, the President & CEO of $RARE ($RARE), sold 8,273 shares of the company on 12-10-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.4% of their...

RARE : 44.22 (+1.73%)
Ultragenyx to Participate in Investor Conferences in December GlobeNewswire - Tue Nov 26, 3:30PM CST

RARE : 44.22 (+1.73%)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Wed Nov 20, 3:30PM CST

RARE : 44.22 (+1.73%)
Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit GlobeNewswire - Sat Nov 9, 9:30AM CST

RARE : 44.22 (+1.73%)
Ultragenyx: Q3 Earnings Snapshot AP - Tue Nov 5, 3:11PM CST

Ultragenyx: Q3 Earnings Snapshot

RARE : 44.22 (+1.73%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads Barchart - Sat Dec 21, 9:15AM CST
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot